2 results
Approved WMOCompleted
Primary objective* To assess the non-inferiority of darunavir/r + raltegravir compared to darunavir/r + tenofovir/emtricitabine as first-line treatment strategies in HIV-1 infected, antiretroviral naïve adults over at least 96 weeks (i.e. to assess…
Approved WMOCompleted
To confirm our previous findings that both TUS and auditory cuing decreases MEP amplitude in an independent sample using a more efficient design. Reducing the number of principal conditions will benefit data quality and allow for better estimation…